Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

There are disclosed compound of formula I, in which R1 represents a hydrophobic moiety adapted to occupy the C' channel of human CDId, R2 represents a hydrophobic moiety adapted to occupy the A' channel of human CDId, such that R1 fills at least at least 30% of the occupied volume of the C' channel compared to the volume occupied by the terminal nC14H29 of the sphingosine chain of a-galactosylceramide when bound to human CDId and R2 fills at least 30% of the occupied volume of the A' channel compared to the volume occupied by the terminal nC25H51 of the acyl chain of a-galactosylceramide when bound to human CDId R3 represents hydrogen or OH, R<a> and R each represent hydrogen and in addition, when R<3> represents hydrogen, R<a>and R together may form a single bond, X represents or -CHA(CHOH)nY or - P(=0)(0<->)0CH2(CH0H)mY, in which Y represents CHB1B2, n represents an integer from 1 to 4, m represents 0 or 1, A represents hydrogen, one of B1 and B2 represents H, OH or phenyl, and the other represents hydrogen or one of B1 and B2 represents hydroxyl and the other represents phenyl, in addition, when n represents 4, then A together with one of B1 and B2 together forms a single bond and the other of B1 and B2 represents H, OH or OSO3H and pharmaceutically acceptable salts thereof the compounds of formula I are indicted for use in the treatment of a virus, microbial infection, parasite, an autoimmune disease, cancer, allergy or asthma.

Type

Journal article

Publication Date

25/10/2006

Addresses

LUDWIG INST CANCER RES